JP2025516139A - ポリペプチド及びその使用 - Google Patents

ポリペプチド及びその使用 Download PDF

Info

Publication number
JP2025516139A
JP2025516139A JP2024561820A JP2024561820A JP2025516139A JP 2025516139 A JP2025516139 A JP 2025516139A JP 2024561820 A JP2024561820 A JP 2024561820A JP 2024561820 A JP2024561820 A JP 2024561820A JP 2025516139 A JP2025516139 A JP 2025516139A
Authority
JP
Japan
Prior art keywords
polypeptide
mice
human
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024561820A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025516139A5 (cg-RX-API-DMAC7.html
Inventor
タン,ジェン
リ,タオ
リ,シュポン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Chenyang Biological Technology Co Ltd
Original Assignee
Shenzhen Chenyang Biological Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Chenyang Biological Technology Co Ltd filed Critical Shenzhen Chenyang Biological Technology Co Ltd
Publication of JP2025516139A publication Critical patent/JP2025516139A/ja
Publication of JP2025516139A5 publication Critical patent/JP2025516139A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1787—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/35—Animals modified by environmental factors, e.g. temperature, O2
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2024561820A 2022-04-21 2023-04-20 ポリペプチド及びその使用 Pending JP2025516139A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202210427358.7 2022-04-21
CN202210427358.7A CN114767832B (zh) 2022-04-21 2022-04-21 多肽及其用途
PCT/CN2023/089490 WO2023202663A1 (zh) 2022-04-21 2023-04-20 多肽及其用途

Publications (2)

Publication Number Publication Date
JP2025516139A true JP2025516139A (ja) 2025-05-27
JP2025516139A5 JP2025516139A5 (cg-RX-API-DMAC7.html) 2026-04-27

Family

ID=82431759

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024561820A Pending JP2025516139A (ja) 2022-04-21 2023-04-20 ポリペプチド及びその使用

Country Status (6)

Country Link
US (1) US20260183408A1 (cg-RX-API-DMAC7.html)
EP (1) EP4512412A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025516139A (cg-RX-API-DMAC7.html)
KR (1) KR20250013150A (cg-RX-API-DMAC7.html)
CN (1) CN114767832B (cg-RX-API-DMAC7.html)
WO (1) WO2023202663A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114767832B (zh) * 2022-04-21 2025-05-16 深圳辰扬生物科技有限公司 多肽及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002061087A2 (en) * 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides
US20080213271A1 (en) * 2005-05-05 2008-09-04 Center For Addiction And Mental Health Compositions and Methods For Modulating Dopamine Nerutransmission
AU2015318567B2 (en) * 2014-09-19 2020-11-05 The Royal Institution For The Advancement Of Learning/Mcgill University Biosensors for monitoring biomolecule localization and trafficking in cells
CN113501881B (zh) * 2017-09-27 2023-07-28 北京大学 融合蛋白
CN109106942B (zh) * 2018-09-18 2019-11-22 深圳瑞健生物科技有限公司 一种可通过血脑屏障的多肽在制备药物中的应用
JP7492733B2 (ja) * 2020-07-21 2024-05-30 公立大学法人横浜市立大学 ドーパミンd2受容体・ドーパ受容体相互作用阻害ペプチド
CN113855784B (zh) * 2021-09-26 2025-04-15 深圳辰扬生物科技有限公司 多肽的抗抑郁、抗焦虑用途及复合体
CN113813364B (zh) * 2021-11-09 2024-06-28 深圳辰扬生物科技有限公司 多肽的抗成瘾及其复发的用途、复合体及多肽
CN114767832B (zh) * 2022-04-21 2025-05-16 深圳辰扬生物科技有限公司 多肽及其用途

Also Published As

Publication number Publication date
CN114767832A (zh) 2022-07-22
EP4512412A4 (en) 2026-04-22
EP4512412A1 (en) 2025-02-26
KR20250013150A (ko) 2025-01-31
US20260183408A1 (en) 2026-07-02
WO2023202663A1 (zh) 2023-10-26
CN114767832B (zh) 2025-05-16

Similar Documents

Publication Publication Date Title
AU2016201712B2 (en) ActRIIb antagonists and dosing and uses thereof
KR101375026B1 (ko) 종양 및 세포의 제거 또는 파괴를 필요로 하는 다른 질환의 치료에 효과적인 펩티드
ES2281529T3 (es) Peptidos eficaces en el tratamiento de tumores y otras afecciones que requieren la eliminacion o destruccion de celulas.
JP6420459B2 (ja) 線維症抑制活性を有するペプチド及びこれを含む組成物
ES2525669T3 (es) Inhibidores de la vascularización
JPH11507332A (ja) 結合組織成長因子
CN1094445A (zh) 作为血管内皮生长因子受体的f1k-1
JP2001515360A (ja) ▲II▼型TGF−βレセプター/免疫グロブリン定常領域融合タンパク質
JP2012520661A (ja) 抗血管新生融合タンパク質
PT2825208T (pt) Proteína de ligação de neurotrofinas p75ntr para utilização terapêutica
EP2328917B1 (en) Neuronal viability factor and use thereof
PT1003545E (pt) Polipéptidos de factor de crescimento que se liga à heparina (hbgf)
CN110869386A (zh) 重组神经生长因子的组合物和方法
ES2329467T3 (es) Utilizacion de heterogublina como factor de crecimiento de celulas epiteliales.
US20200048318A1 (en) Myomerger polypeptides, nucleic acid molecules, cells, and related methods
US8808691B2 (en) Method for treating tumors and their metastases
EP4512412A1 (en) Polypeptide and use thereof
JP2023133582A (ja) ペプチド並びにそれを含む細胞融合剤及びがん治療用医薬組成物
JP2024535104A (ja) ポリペプチドおよび複合体の抗うつ用途および抗不安用途
US6630325B1 (en) Compositions, methods and kits relating to remodel
CN116262785A (zh) 抗抑制素抗体及其应用
AU2003288434A1 (en) Peptides, antibodies thereto, and their use in the treatment of central nervous system damage
HK40121458A (en) Polypeptide and use thereof
KR101697771B1 (ko) Itm2a 폴리펩타이드 또는 이를 암호화하는 핵산을 유효성분으로 하는 항암용 조성물
US20220362359A1 (en) Dna vaccine capable of effectively treating and/or preventing type 1 diabetes and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260417

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260417